secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2023-12-21T23:59:59+00:00
Accession:  0001213900-23-097738
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 3.02, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix acquires Proteomedix AG in $75M share exchange; pre-closing holders diluted to 5.4%
--------------------------------------------------------------------------------

- Exchange consideration: 4,083,779 common shares plus 2,692,633 Series B convertible preferred (convertible into 269,263,300 common).
- Post-closing ownership: Sellers 79.8%, new Investor 5.9%, pre-closing Onconetix stockholders 5.4%.
- Series B convertible preferred auto-converts on stockholder approval; cash settlement if approval not obtained by Jan 1, 2025.
- Lock-up on Exchange Shares and Conversion Shares for 6 months after stockholder approval.
- Post-approval board: 5 directors – 3 designated by Proteomedix, 2 by Onconetix.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/0001213900-23-097738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395-8k_onconetix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-097738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer